The Burden of Sarcoidosis Symptoms from a Patient Perspective

• DOI: 10.1007/s00408-019-00206-7
• Publication Date: 2019-02-18T05:19:03Z
• Authors: M. Voortman; C. M. R. Hendriks; M. D. P. Elfferich; F. Bonella; J. Møller; J. De Vries; U. Costabel; M. Drent
• Keywords: Glucocorticoids/therapeutic use; Pulmonary and Respiratory Medicine; Adult; Male; Adolescent; Sarcoidosis; IMPACT; Medizin; Prednisone/therapeutic use; FATIGUE; Interstitial Lung Disease; Europe/epidemiology; Young Adult; Cost of Illness; QUALITY-OF-LIFE; Small fiber neuropathy (SFN); Prevalence; Humans; Child; Glucocorticoids; Fatigue; Aged; Aged, 80 and over; Fatigue Assessment Scale (FAS); Small fiber neuropathy screenings list (SFNSL); Sarcoidosis-associated symptoms; SMALL FIBER NEUROPATHY; Middle Aged; Sarcoidosis/diagnosis; Prognosis; Health Surveys; PREVALENCE; 3. Good health; Europe; Cross-Sectional Studies; Disease Progression; Prednisone; Female

The clinical manifestations of sarcoidosis vary widely, depending on the intensity of the inflammation and the organ systems affected. Hence, sarcoidosis patients may suffer from a great variety of symptoms. The aim of this study was to compare the self-reported burden of sarcoidosis patients in Denmark, Germany and the Netherlands, especially the prevalence of fatigue and small fiber neuropathy (SFN)-related symptoms, as well as differences in treatment strategies.A cross-sectional web-based anonymous survey about complaints was conducted among sarcoidosis patients. Patients were invited to take part through the sarcoidosis patient societies as well as through outpatient sarcoidosis clinics in these countries.The questionnaire was completed by 1072 sarcoidosis patients (152 Danish, 532 German and 388 Dutch). Almost all patients reported having sarcoidosis-associated symptoms (organ-related as well as non-specific, non-organ related). Fatigue was reported by almost all respondents (90%), followed by pulmonary symptoms (72.4%). More than 50% of the respondents were being treated with prednisone, which was comparable in all three countries. In contrast, second- and third-line treatment differed substantially between Denmark, Germany and the Netherlands.Sarcoidosis patients in Denmark, Germany and the Netherlands present with similar self-reported symptoms, organ-related as well as non-specific, non-organ related. Fatigue (90%) and symptoms associated with SFN (86%) were highly prevalent in all three countries.